Faculty within the Department of Urology actively engage in multi-disciplinary investigation to improve the quality and value of health care delivered to patients with benign and malignant urologic disease. Faculty within the Vanderbilt Department of Urology continue to lead landmark studies characterizing the downstream effects of prostate cancer and its treatment. Furthermore, ongoing research within the Department seeks to bridge the gap between health services research and quality improvement to optimize care delivered to patients at Vanderbilt and across the United States.
David F. Penson, M.D., MPH
As the Hamilton and Howd Chair of Urologic Surgery and Co-Director of the Center for Surgical Quality and Outcomes Research (CSQOR), Dr. Penson maintains an active research program dedicated to characterizing the comparative effectiveness of various management strategies for men with prostate cancer. Dr. Penson is an international expert in patient-reported outcomes, and has made substantive contributions to the field of prostate cancer survivorship. Dr. Penson serves as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) Study, a prospective cohort study of over 3,500 men with newly diagnosed prostate cancer. The purpose of the study is to evaluate both the comparative effectiveness and harms of different management strategies for prostate cancer and to identify patient-specific factors that mediate the effectiveness or side effects of different treatments.
Daniel A. Barocas, M.D., MPH
Dr. Barocas is currently Associate Professor of Urology and Co-Director of CSQOR. Dr. Barocas serves as Co-Principal Investigator of the CEASAR Study, and has largely served as a catalyst for evaluation of prostate cancer quality of care within the CEASAR cohort. Dr. Barocas has a deep interest in health care quality measurement, specifically as it relates to the management of genitourinary malignancies. Furthermore, Dr. Barocas is actively working to develop natural language processing algorithms within the Vanderbilt electronic medical record to facilitate estimation of extent of disease, and ultimately, measure cancer care quality.
Matthew J. Resnick, M.D., MPH
Dr. Resnick is currently Associate Professor of Urology and Health Policy at Vanderbilt University Medical Center. Dr. Resnick’s research program aims to characterize the effect of health care delivery system reform on cancer diagnosis, treatment, and survivorship. He was recently awarded funding from the American Cancer Society to evaluate the effect of Accountable Care Organization enrollment on appropriateness of breast, colorectal, and prostate cancer screening. Dr. Resnick is particularly interested in the development and deployment of novel payment models particularly related to cancer care delivery, and is actively working towards developing models for incentive alignment between primary care and specialty physicians.
W. Stuart Reynolds, M.D., MPH
W. Stuart Reynolds, MD, MPH, is Assistant Professor of Urology at Vanderbilt University Medical Center. As core faculty in the division of Female Pelvic Medicine and Reconstructive Surgery, Dr. Reynolds’ research focuses on health services and outcomes research related to benign lower urinary tract disorders and pelvic reconstruction. His current research examines the effects of biomarkers of pathophysiologic disease mechanisms and patient phenotyping on treatment outcomes in women with overactive bladder syndrome.